Israeli biotech KAHR Medical plans to trial KAHR-102, one of its groundbreaking Signal Converting Proteins (SCP), for the treatment of lymphatic cancer.
http://www.kahr-medical.com/dynamic.asp?cid=10472&ttl=strip3
http://www.globes.co.il/serveen/globes/docview.asp?did=1000878189&fid=1725
http://www.youtube.com/watch?v=pV6ibvvg5Xo